BioNTech's mRNA Mpox Vaccine Candidate Enters Clinical Trial Phase
BioNTech SE is conducting a randomized clinical trial to evaluate the safety and immunogenicity of its mRNA-based Mpox vaccine candidate.
Therapeutic Area
Therapeutic area intelligence for Vaccine with 10 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.